Daiichi Sankyo Company, Ltd. announced on Monday that SAVAYSA, a once-daily, oral, selective factor Xa-inhibitor, is now available in pharmacies within the United States.
SAVAYSA, approved by the U.S. Food and Drug Administration on Jan. 8, is used to decrease the risk of stroke and systemis embolism (SE) in patients with non-valvular atrial fibrillation (NVAF). It is also used to treat deep vein thrombosis and pulmonary embolism after 5 to 10 days of parenteral anticoagulant therapy.
“The availability of SAVAYSA provides appropriate patients and their physicians with a new anticoagulant that has been shown to reduce the risk of stroke and SE with significantly less major bleeding compared to warfarin in patients with NVAF and that treats venous thromboembolism with significantly less clinically relevant bleeding compared to warfarin,” Howard Rutman, vice president of medical affairs at Daiichi Sankyo, said.
To accompany the launch of SAVAYSA, Daiichi launched the SAVAYSA Savings Plus program, which includes a reimbursement hotline to help patients and prescribers who have questions on a patient’s coverage. Eligible patients can enter the copay saving program and pay $4 per month for their SAVAYSA prescription. Daiichi also will offer patients and doctors vouchers so that patients can see if SAVAYSA is right for them at no cost.
Alerts Sign-up